Personalized medicine for cancer treatment
Official title: Evaluating the Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer Patients: A Prospective Longitudinal Trial
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT05830279 · Data updated 2026-11-12
This study is testing if personalized medicine recommendations can improve how well antidepressants, pain medications, and anti-nausea drugs work for cancer patients by looking at their genetic makeup and medication interactions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (London, Ontario) |
| Status | Recruiting |
| Started | May 1, 2023 |
| Main results expected | April 30, 2026 |
| Study ends | April 30, 2026 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT05830279 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult cancer patients aged 18 and older who are prescribed chemotherapy and taking specific antidepressants, analgesics, or antiemetics.
✕Probably not a fit
Patients receiving palliative care or those taking antidepressants for reasons other than depression or anxiety may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the impact of personalized medicine recommendations on the pharmacogenetic variations and drug interactions affecting the effectiveness and toxicity of antidepressants, pain medications, and antiemetics in cancer patients. Participants will be assigned to one of three cohorts based on their prescribed medications and will undergo pharmacogenetic testing and drug-drug interaction analysis. The study will assess drug concentration and therapeutic effectiveness before and six months after the recommendations are provided, utilizing patient-reported outcomes to measure symptoms of depression, pain, and chemotherapy-induced nausea/vomiting.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer medication regimens for cancer patients, improving their quality of life.
How similar studies have gone: Other studies have shown promise in using pharmacogenetic approaches to optimize medication therapy in cancer patients, indicating potential success for this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Prescribed a chemotherapy medication * Currently taking one or more study medications (citalopram, escitalopram, venlafaxine, desvenlafaxine, codeine, oxycodone, hydrocodone, tramadol or ondansetron) Exclusion Criteria: * Patients who are unable to complete study materials (surveys) with or without assistance, including non-English speaking patients * Patients receiving palliative care * Patients taking anti-depressants for reason other than depression or anxiety, i.e. hot flash (Only applies to antidepressant cohort) * Patients with preexisting major depressive disorder prior to cancer diagnosis (Only applies to antidepressant cohort)
Where it's running
-
Lawson Health Research Institute
London, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Richard Kim, MD — Western University, Canada
- Study coordinator: Richard Kim, MD
- Email: richard.kim@lhsc.on.ca
- Phone: 519-685-8500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Triple-target radiosurgery for cancer pain using pituitary and thalamic neuromodulation
This study tests whether focused brain radiosurgery to the pituitary and specific thalamic regions can reduce pain in adults with cancer that’s not controlled by opioids or other treatments.
-
Hydromorphone plus electroacupuncture and ear acupressure for refractory cancer pain
This trial tests whether adding electroacupuncture and ear acupressure to hydromorphone extended-release tablets helps relieve refractory cancer pain.
-
Tibetree topical herbal plasters for people using opioids for cancer pain
This trial will try Tibetree topical herbal plasters together with prescribed opioids to see if they reduce localized cancer-related pain for adults who are currently taking short-term oral opioids.
-
Transdiscal versus paravertebral splanchnic nerve neurolysis for upper abdominal cancer pain
This will test whether the transdiscal or the paravertebral splanchnic nerve neurolysis gives better pain relief for people with severe upper abdominal cancer pain that hasn't responded to medicines.
-
MRI-guided focused ultrasound mesencephalotomy for opioid-resistant head, neck, and brachial cancer pain
This study will try MRI-guided focused ultrasound to make a tiny, precise lesion in the midbrain to relieve severe, opioid-resistant head, neck, or brachial cancer pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.